Ernexa Therapeutics, Inc. (ERNA)
0.1951
-0.01
(-5.34%)
USD |
NASDAQ |
Apr 10, 16:00
0.1953
0.00 (0.00%)
After-Hours: 20:00
Ernexa Therapeutics Cash from Financing (Quarterly) : 0.00 for Dec. 31, 2025
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Ocular Therapeutix, Inc. | 449.38M |
| Quince Therapeutics, Inc. | 1.376M |
| Recursion Pharmaceuticals, Inc. | 132.01M |
| Tango Therapeutics, Inc. | 219.38M |
| Aprea Therapeutics, Inc. | 4.004M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.148M |
| Cash from Investing (Quarterly) | -0.015M |
| Free Cash Flow | -7.054M |
| Free Cash Flow Per Share (Quarterly) | -0.1481 |
| Free Cash Flow to Equity (Quarterly) | -1.101M |
| Free Cash Flow to Firm (Quarterly) | -1.163M |
| Free Cash Flow Yield | -193.8% |